FDA Approves Novocure’s Brain Cancer Treatment Optune

October 13, 2015 | Israel’s Novocure‘s medical device Optune, which treats adult patients with glioblastoma brain tumors, has just been approved by the U.S. Food and Drug Administration (FDA). Optune is a portable, non-invasive device that delivers low-intensity, intermediate frequency, alternating electric fields – referred to as Tumor Treating Fields (TTFields) – that inhibit cancer cell replication and cause cancer cell death. Founded in Israel in 2000, the company’s main operations are in the US.